Category Archives: New Mexico Stem Cells

The global stem cell and regenerative medicines market should grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11723

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

Make an Inquiry before Buying:https://www.trendsmarketresearch.com/checkout/11723/Single

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

Request for Report Discount:https://www.trendsmarketresearch.com/report/discount/11723

See the original post here:
Stem Cell And Regenerative Therapy Market Research Insights Global Industry Outlook Shared in Detailed Report, Forecast size 2024 - Daily Science

https://www.facebook.com/BYUNewsline/videos/139784500762291

SANDY With the numbers of coronavirus increasing, its understandable why people are getting a little nervous. But people like Heidi Petersen have more reason to worry than most because she has multiple sclerosis, an autoimmune disease where the bodys immune system attacks its own tissues. What do people like her do in a pandemic like this?

They do their best.

Heidi was diagnosed with MS in July 2015. As her body started shutting down, she welcomed an opportunity to get better: a procedure in Mexico called HSCT that would reboot her immune system. After months of saving and kind donations, Heidi had the procedure done in August 2019.

While exciting, the process wasnt easy. She had her stem cells removed, underwent chemotherapy, then had her stem cells put back. The process wiped out all her previous immunizations and she was left with the immune system of a newborn baby. Because of the new immune system, she had to be completely isolated in a sterilized house for six months.

After six months, Heidi had two blissful weeks to go out and see her family and eat at all the restaurants shed been dreaming about.

Enter coronavirus.

Now, Heidis back to isolation because she is a high-risk case of severe illness if she were to contract coronavirus.

One of the frustrating things for me is when I see people talk so nonchalantly about [the coronavirus], said Heidi. They say, Oh well, it doesnt matter, Im healthy. Well it does matter! Because youre putting a lot of people at risk by not following the rules.

Heidi explained that those at high-risk arent concerned about stocking up on toilet paper; theyre worried about getting their medications. Theyre worried to even step outside their doors!

But luckily, there are ways people can be more sensitive to the needs of others. Heidi suggested that it starts with being a good neighbor and checking up on those who are immunocompromised or elderly. Offer to drop off groceries at their door or simply give them a phone call to ask if theyre okay.

The biggest consideration, said Heidi, is to stay away from large gatherings, wash your hands and dont stockpile on things you dont need.

Heidis plea is that everyone simply think about how their actions are affecting others. She believes that if everyone comes together against this disease, it will stop spreading and help so many people who are at risk.

Just help each other out, she said, and well all make it through this.

Read the original:
At risk: Braving the coronavirus with a compromised immune system - Universe.byu.edu

The Abortion Lobby has taken political operative Rahm Emanuels infamous advice to heart: You never want a serious crisis to go to waste. And what I mean by that is an opportunity to do things that you think you could not do before. In some unprecedented power grabs, abortion advocates are using the crisis of the coronavirus to infiltrate the medical profession and taxpayer resources with political overreach that attempts to make the business of abortion the one thing in America that doesnt come to a halt.

Overreach #1: Pretending that abortion is healthcare, an essential service. The abortion industry has argued that in light of the need to prioritize essential and nonessential care for Covid-19 sufferers and the public at large, abortion must be considered a vital procedure.

The American College of Obstetricians and Gynecologists made a public statement calling for uninterrupted abortions as an essential component of comprehensive health care. It was a view that the abortionists lobby, the National Abortion Federation, shared in spades, saying, During this public health crisis, pregnancy care, including abortion care, remains an essential health service Abortion is provided for almost one in five pregnancies in the United States, as part of the continuum of pregnancy care. A continuum that ends in death, if the abolitionist gets a fee.

Some states initially determined that abortion needed to be prioritized, such as in Massachusetts and New York, but that is changing in some locations.

In Ohio, Attorney General Dave Yost ordered abortion vendors to stop the abortion surgeries though in the same timeframe The Womens Med Center of Dayton and Planned Parenthood of Greater Ohio told the Dayton Daily News that they will remain open.

Meera Shah, chief medical officer for Planned Parenthood in the New York City suburbs of Long Island, Westchester, and Rockland told Buzzfeed that they wouldnt close, saying, Pregnancy-related care, especially abortion care, is essential and life-affirming.

Seriously? Far from an essential service, abortion is not a treatment curing pregnancy. Prioritizing ending life in the name of a life-ending virus is heartless in the extreme.

Overreach #2:Trying to coerce more healthcare workers to end life. ACOG advises, Community-based and hospital-based clinicians should consider collaboration to ensure abortion access is not compromised during this time."

Talking with the Huffington Post, the Very Rev. Katherine Hancock Ragsdale, president of the National Abortion Federation, echoed the desire to address what the abortion-supporting think tank the Guttmacher Institute calls a shortage of clinicians who can provide sexual and reproductive health services.

One or two people unable to show up can make the difference between a clinic being able to function or not, she said, arguing for more physicians to join in a business that ends life to replace any abortionists who cant work.

This pitch comes as abortionist shortages exist nationwide not because of a virus, but because real healthcare professionals dont want to kill preborn babies through abortion.

Overreach #3: Urging Americans to stock up on birth control so that when the quarantine is over, we dont welcome new life. Planned Parenthood lectures Americans about not using their alone time to result in a Coronavirus Baby Boom. Dont worry, says the Associated Press, Family planning providers around the country are taking steps to help prevent a boom in pregnancies due to coronavirus self-isolation.

We remain committed to delivering compassionate, non-judgmental reproductive and sexual health care to all who need it while we take proactive measures to stay as far ahead of COVID-19 as possible," said Meagan Gallagher, chief executive officer of Planned Parenthood of Northern New England, to the AP.

But its pretty judgmental to lecture people that new life will be unwelcome.

Overreach #4:Insinuating that without human organs from aborted infants, there will be a delay in treatment for coronavirus sufferers.

This kind of heartlessness strikes at the fear that treatment could be delayed without opening up another profit center for abortion vendors the sale of human remains, the broken bodies of aborted infants. The Washington Post, in a recent report, noted the complaints of a researcher who wanted infant remains, despite the fact that many cell lines are available for use and that successful treatments have come from ADULT stem cells, not aborted fetal cells.

The Charlotte Lozier Institute notes that fetal cells have not been used to create vaccines, such as needed today for Covid-19. Consider that the historical fact is that fresh aborted fetal tissue has never been used in vaccine production. The original Salk and Sabin polio vaccines used monkey tissue to grow virus. While there are a couple of historical cell lines that were grown from abortions in the 1960s, kept in cell culture, and used for some vaccines, even these cell lines are obsolete and no longer used for most vaccines today.

Overreach #5: Pressuring the FDAto reduce the medical standards for distributing life-ending abortion drugs, so that they can be handed out in ways known to harm women. Abortion drugs given to women later in pregnancy or experiencing an ectopic pregnancy have resulted in womens deaths, leading to regulations from the FDA that include a physical examination for womens safety.

But that hasnt stopped abortion vendors from trying to sell the pills on-line or pushing for reduced safety standards so they can make a buck faster.

Leading abortionist Dr. Daniel Grossman called telemedicine the perfect solution for women looking to terminate early pregnancies, according to Mother Jones unless you care about complications to hurting women, that is.

Overreach #6: Attempting to infiltrate the Covid-19 aid package with healthcare dollars that could be used for abortions. Faced with a nation fearing disastrous consequences from the coronavirus, what did abortion extremists in the U.S. House of Representatives do? Add healthcare dollars that could be used to pay for abortions. But President Trump and pro-life allies were able to win Hyde Amendment protections to keep the package focused on disaster relief not taxpayer funded abortion.

Overreach #7:Pretending that the pro-life policies of the Trump administration have harmed current life-saving efforts. The Guttmacher Institute, in detailing their complaints of the Covid-19 response, listed a number of policies, from limiting taxpayer funds from paying for abortions around the world (the Mexico City Policy) to changes in the Title X program that wont allow abortion vendors to market their services to women looking for family planning services. What do those things have to do with Covid-19? Nothing, but that doesnt stop the complaints.

In a recent fundraising appeal, Planned Parenthood Action Fund (PPAF) asked for donation as they told supporters, We are working tirelessly to ensure that everyone gets the care they need, and to advocate for policies that protect and expand our health and rights. A strange appeal at a time in which the life-saving care that people should be donating to for their actual health is taking place everywhere but in abortion facilities. But in a business marked by crass opportunism, what more do you expect.

Go here to read the rest:
The Answer to the Coronavirus Is More Abortion? - Townhall

The global stem cell and regenerative medicines market should grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11723

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

Make an Inquiry before Buying:https://www.trendsmarketresearch.com/checkout/11723/Single

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

Request for Report Discount:https://www.trendsmarketresearch.com/report/discount/11723

Visit link:
Stem Cell And Regenerative Therapy Market size receive overwhelming hike in Revenues by 2024 - Daily Science

2020 is already promising to be a fantastic year for space exploration. The next generation of Artemis explorers can begin applying for the program that will be journeying to the Moon, Mars and beyond; the James Webb Space Telescope is ready to test key deployments made in space, and even the Orion spacecraft that will blast off to the Moon during Artemis missions has successfully passed its final tests. Furthermore, NASA and commercial space companies prepare for the colonization of orbit, rockets are taking payloads to the International Space Station (ISS) very often and 3D bioprinting is becoming an attractive and useful method to carry out experiments. The next one up is SpaceX mission CRS-20. Scheduled to launch at 11:50 PM Eastern Time (EST) on March 6 from Floridas Cape Canaveral Air Force Station, the unpiloted cargo spacecraft is expected to arrive at the orbiting laboratory two days later with three Techshot-managed research campaigns.

The Indiana-based commercial research company is sending equipment and samples supporting plant, heart and cartilage research for NASA, Emory University and the Uniformed Services University of the Health Sciences (USU) to the ISS. According to the company, astronauts onboard the station will use Techshots 3D BioFabrication Facility (BFF) mounted inside the ISS U.S. National Laboratory (ISS National Lab) since last summer to manufacture human knee menisci for the 4-Dimensional Bioprinting, Biofabrication, and Biomanufacturing, or 4D Bio3program. Based at USU, 4D Bio3 is a collaboration between the USU and The Geneva Foundation, a non-profit organization that advances military medical research.

Funded by the U.S. Defense Health Program and managed by the Geneva Foundation, 4D Bio3promotes the development and application of advanced bioprinting, biofabrication, and biomanufacturing technologies for research pursuant to U.S. Department of Defense priorities and ultimately for translation to clinical medical defense care and training solutions.

This is our most diverse manifest to date, said Techshot President and CEO, John Vellinger. Throughout March well be conducting three major investigations in space for three customers using three very different Techshot-built research devices. Its going to be a busy month, but were excited to see the results.

Techshot owns BFF and the company built it at a cost of approximately seven million dollars. The starting point was an nScrypt printer, which now is highly modified by Techshot for use inside the ISS. In that relationship, Techshot handles all the space bioprinting, while nScrypt handles all the Earth-based bioprinting.

This first experiment for 4D Bio3 next month will be used as a test of the materials and the processes required to print a meniscus in space. Techshot engineers will upload a design file to BFF from the companys Payload Operations Control Center in Greenville, Indiana, and evaluate its success via real-time video from inside the unit. A second meniscus print will take place in BFF early next year and the item will then be returned to Earth for extensive testing and comparison to the nScrypt Earth-printed items. Last year nScrypt printed the same thing at a U.S. military base in Africa with their own printer.

Vincent B.Ho, Director of 4D Bio3 and professor and chair of radiology at USU said that meniscal injuries are one of the most commonly treated orthopedic injuries, and have a much higher incidence in military service membersreported to be almost 10 times that of the civilian population. We successfully biofabricated 3D human medial and lateral menisci in a pilot study performed in Africa last summer and anticipate learning valuable lessons on the challenges and benefits of biofabrication in microgravity by performing a similar experiment on the space station.

Besides BFF, there are four other Techshot owned and operated research machines inside the ISS today. Only the BFF is a bioprinter. The others are an X-ray machine for mice, two identical units called the Techshot Multi-use Variable-gravity Platform (MVP), and one called the ADvanced Space Experiment Processor (ADSEP), which is where cells printed in the BFF go to become conditioned and cultured into the tissue. The company has agreements with NASA and the ISS National Lab that permit Techshot to operate a commercial business in space. This is part of NASAs objective to make orbit more commercial, providing access to space for nearly anyone.

Another complex Techshot-managed experiment launching onboard SpaceX CRS-20 will test whether a heart-specific stem cell, called a cardiac progenitor, multiplies better in space and if more of them become heart muscle cells known as cardiomyocytes. This is part of Chunhui Xu, an associate professor in the department of pediatrics at the Emory University School of Medicine who studies heart cells, research that aims to improve treatments for congenital heart disorders and better the hearts ability to regenerate after injuries.

Preparing the experiments: under the vent hood, Biomedical Engineer Jordan Fite adds media to bags and fluid loops that will be used in the experiment in space (Image: Techshot)

Techshot explained that human cardiac tissues cant repair themselves once damaged from disease, due to this, repairing a failing heart by cell therapy requires a large number of cardiomyocytes, which can be converted from stem cells cultured in two dimensions in Earth-based laboratories. Without the pull of gravity, it is expected that culturing in three dimensions in space, inside specialized Techshot cell culture experiment modules, will increase the yield of high-quality heart muscle cells. The company expects that learning more about why this happens could lead to new strategies for reproducing the same results on a much larger scale on Earth, lowering costs and enabling more patients to receive needed cardiac cell therapies.

Astronaut handling Techshots BFF (Image: Techshot/NASA)

It is expected that once the cargo spacecraft reaches the station, the 12 Techshot experiment modules will be removed from the spacecraft and inserted by the crew into the companys Multi-use Variable-gravity Platform (MVP) unit number two mounted in the Japanese space laboratory known as Kibo.

We are thankful for Techshots engineers who designed the Multi-use Variable-gravity Platform hardware and will help us maintain constant communication with the astronauts during the flight operation. Their professionalism and collaboration with our team have contributed tremendously toward our overall research efforts, said Ho.

Besides the materials for the BFF meniscus print, SpaceX CRS-20 will also carry 12 Passive Orbital Nutrient Delivery System, or PONDS, plant growth devices that Techshot co-developed with Tupperware Brands, and that was first prototyped by NASA Kennedy Space Center. According to company officials, they will be growing red romaine lettuce inthe devices, installed inside two of the space stations identical plant growth chambers each called Veggie. The PONDS units are being tested in two different configurations, each representing approaches refined from two previous flight tests. For this demonstration, lettuce is expected to grow in space for 21 days. Besides the hardware built and own, Techshot also manages the space stations most complex greenhouse, called the Advanced Plant Habitat, and it manages two on-orbit research furnaces called PFMI and SUBSA.

Techshot has been working hard to get samples ready in a lab at the Space Station Processing Facility at NASAs Kennedy Space Center.

Product assurance associate Keri Roeder, program manager Nathan Thomas and mechanical engineer Grant Vellinger prepared samples for Techshot customer Emory University (Image: Techshot)

Founded more than 30 years ago, Techshot operates its own commercial research equipment in space and serves as the manager of three NASA-owned ISS payloads. The company is also working on other space 3D printing technologies. Last fall they tested a laser-based 3D metal printer in zero gravity inside an aircraft performing parabolic arcs over the Gulf of Mexico (sometimes unofficially nicknamed the vomit comet). However, officials suggest that this technology is still at least a couple of years from Techshot launching it to the space station.

NASA and dozens of companies continue to work together to develop the means for astronauts and space explorers to endure life in orbit, the Moon and other planets. This vision is enthralling for anyone who ever dreamed of going to space, even hopeful of the next generations that will be able to experience space travel and conduct research work in microgravity. Perhaps we are too hopeful of the future, but with so much going on, its difficult not to be.

The launch on Friday will be the last SpaceX launch under the current NASA CRS-1 contract, yet SpaceX will continue performing resupply missions under a new CRS-2 contract beginning with the next scheduled resupply mission in August this year. To watch the launch, which is scheduled to take place at 11:50 p.m. EST on Friday, March 6, and capture of the spacecrafts arrival at the ISS, you can tune into NASA TV using the video below:

Original post:
Techshots New Projects Will be on the Next SpaceX Mission Launch - 3DPrint.com

TEL AVIV, Israel, Feb. 27, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of motixafortide (BL-8040), a novel immunotherapy compound, combined with any PD-1 inhibitor, for the treatment of any type of cancer.

The PD-1 antagonist can be any agent that prevents and/or inhibits the biological function and/or expression of PD-1, such as pembrolizumab (KEYTRUDA). The targeted cancer can be solid, non-solid, and/or a cancer metastasis.

This patent, whenmedi issued, will be valid until July 2036 with a possibility of up to five years patent term extension. Additional corresponding patent applications are pending in Europe, Japan, China, Canada, Australia, India, Korea, Mexico, Brazil and Israel.

"We are extremely pleased to receive this valuable notice of allowance from the USPTO, which entitles us to long-term, highly enforceable and broad patent protection for our lead product, motixafortide, in combination with any PD-1 inhibitor, and more importantly, for all cancer indications, including, of course, any solid tumor," stated Philip Serlin, Chief Executive Officer of BioLineRx. "This important patent allowance also supports our ongoing Phase 2a COMBAT/KEYNOTE-202, for which we have recently completed patient recruitment in the triple combination arm investigating the safety, tolerability and efficacy of motixafortide, KEYTRUDA and chemotherapy. Following promising initial results demonstrating robust and durable responses to the triple combination treatment, we look forward to the progression-free and overall survival data from the triple combination arm expected in mid-2020."

The COMBAT/KEYNOTE-202 Study

The Phase 2a COMBAT/KEYNOTE-202 study was originally designed as an open-label, multicenter, single-arm trial to evaluate the safety and efficacy of the dual combination of motixafortideand KEYTRUDA (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada), in over 30 subjects with metastatic pancreatic adenocarcinoma. The study was primarily designed to evaluate the clinical response, safety and tolerability of the combination of these therapies, and was carried out in the US, Israel and additional territories. The study is being conducted by BioLineRx under a collaboration agreement signed in 2016 between BioLineRx and MSD, through a subsidiary.

In July 2018, the Company announced the expansion of its immuno-oncology collaboration with MSD to include the triple combination arm investigating the safety, tolerability and efficacy of motixafortide, KEYTRUDA and chemotherapy as part of the Phase 2a COMBAT/KEYNOTE-202 study. In January 2020, the Company announced completion of recruitment of the 40 patients planned for the triple combination arm of the study.

About Motixafortide in Cancer Immunotherapy

Motixafortideis targeting CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed in many human cancers including PDAC. CXCR4 plays a key role in tumor growth, invasion, angiogenesis, metastasis and therapeutic resistance, and CXCR4 overexpression has been shown to be correlated with poor prognosis.

Motixafortideis a short synthetic peptide used as a platform for cancer immunotherapy with unique features allowing it to function as a best-in-class antagonist of CXCR4. It shows high-affinity, long receptor occupancy and acts as an inverse agonist.

In a number of clinical and preclinical studies, motixafortidehas been shown to affect multiple modes of action in "cold" tumors, including immune cell trafficking, tumor infiltration by immune effector T cells, and reduction in immunosuppressive cells (such as MDSCs) within the tumor niche, turning "cold" tumors, such as pancreatic cancer, "hot" (i.e., sensitizing them to immune checkpoint inhibitors and chemotherapy).

About BioLineRx

BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX) is a clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company's lead program, motixafortide, is a cancer therapy platform currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA and chemotherapy under a collaboration agreement with MSD. Motixafortideis also being evaluated in a Phase 2b study in consolidation AML and a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook,Twitter, and LinkedIn.

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2019. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Tim McCarthyLifeSci Advisors, LLC+1-212-915-2564[emailprotected]

or

Tsipi HaitovskyPublic Relations+972-52-598-9892[emailprotected]

SOURCE BioLineRx Ltd.

http://www.biolinerx.com

See the article here:
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any...

Cells constitute discrete units of biological function and serve as starting points in a myriad of studies to identify and map many of the basic biochemical and physical processes of life. Cell analysis is a wide term that can be applied to a range of different technologies, the technology used depends on experimental needs. Compiling data sets from multiple cell analysis investigations allows scientists to better understand, predict, and ultimately influence the factors that underlie cell health, function, death, and proliferation.

This intelligence report provides a comprehensive analysis of the Global Cell Analysis Market. This includes Investigation of past progress, ongoing market scenarios, and future prospects. Data True to market on the products, strategies and market share of leading companies of this particular market are mentioned. Its a 360-degree overview of the global markets competitive landscape. The report further predicts the size and valuation of the global market during the forecast period. Some of the key players profiled in the study are Thermo Fisher Scientific, Inc. (United States), Danaher Corporation (United States), The Merck KGaA Group (Germany), Becton, Dickinson and Company (United States), GE Healthcare (United States), Agilent Technologies, Inc. (United States), Olympus Corporation (Japan), PerkinElmer, Inc. (United States), Promega Corporation (United States), Sysmex Corporation (Japan) and AbbVie, Inc.(United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Lonza Group (Switzerland), Tecan Group (Switzerland), Miltenyi Biotec (Germany), Stemline Therapeutics, Inc.(United States), Fujifilm Irvine Scientific (United States), STEMCELL Technologies Inc. (Canada), Sino Biological Inc. (United States), BIOTIME, Inc. (United States), Miltenyi Biotec (Germany), PromoCell GmbH (Germany), Carl Zeiss (Germany), Bio-Rad Laboratories Inc (United States), MacroGenics, Inc. (United States), OncoMed Pharmaceuticals, Inc. (United States) and Bionomics (Australia).

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/124696-global-cell-analysis-market

Market Trend

Market Drivers

Restraints

Opportunities

Each segment and sub-segment is analyzed in the research report. The competitive landscape of the market has been elaborated by studying a number of factors such as the best manufacturers, prices and revenues. Global Cell Analysis Market is accessible to readers in a logical, wise format. Driving and restraining factors are listed in this study report to help you understand the positive and negative aspects in front of your business.

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market.Furthermore, the years considered for the study are as follows:Historical year 2013-2017Base year 2018Forecast period** 2019 to 2025 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.The Global Cell Analysis segments and Market Data Break Down are illuminated below:Type (Flow Cytometry Products (Reagents and Consumables, Instruments, Accessories, and Software), QPCR Products (Reagents and Consumables, and Instruments), Cell Microarrays (Consumables, and Instruments), Microscopes (Electron, Inverted, Stereo, and Near-field Scanning Optical), Spectrophotometers (Single-mode Readers, and Multi-mode Readers), Cell Counters (Automated Cell Counters, Hemocytometers, and Manual Cell Counters), HCS Systems, Others)

Application (Cell Culture, Cell Imaging, Cell Isolation and Expansion, Cell Signaling Pathways, Cell Structure, Cell Tracing & Tracking, Cell Function Assays, Stem Cell Research, Others), End Use Verticals (Hospitals and Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Research Institutes, Cell Culture Collection Repositories, Others), Process (Cell Identification, Cell Viability, Cell Signaling Pathways/Signal Transduction, Cell Proliferation, Cell Counting and Quality Control, Cell Interaction, Target Identification and Validation, Single-cell Analysis)

.

.

Enquire for customization in Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/124696-global-cell-analysis-marketRegion Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Objectives of the Study

Read Detailed Index of full Research Study at @ https://www.advancemarketanalytics.com/reports/124696-global-cell-analysis-market

Strategic Points Covered in Table of Content of Global Cell Analysis Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Cell Analysis market

Chapter 2: Exclusive Summary the basic information of the Cell Analysis Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Cell Analysis

Chapter 4: Presenting the Cell Analysis Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Cell Analysis market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data SourceKey questions answered

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

Contact US :

Craig Francis (PR & Marketing Manager)AMA Research & Media LLPUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us athttps://www.linkedin.com/company/advance-market-analyticshttps://www.facebook.com/AMA-Research-Media-LLP-344722399585916https://twitter.com/amareport

Read the original post:
Cell Analysis Market is Expected to See Growth Rate of 6.96% - Nyse Nasdaq Live

Stem Cell Cartilage Regeneration Market outlook 2020, is a professional and comprehensive study on the current state of the global Stem Cell Cartilage Regeneration Industry with a focus on the global market. Stem Cell Cartilage Regeneration Market Report provides extensive information which advances the understanding, scope and application of this report. Global Stem Cell Cartilage Regeneration Market research report provides a real industry outlook, future trends and dynamics for market size, shares, growth rate, trends and key players. The analysts of report offer an intricate description of the value chain and its distributor analysis. The comprehensive primary analysis report highlights numerous facets such as development factors, growth factors, key opportunities, challenges, business enhancement strategies, financial gain, statistical growth or loss to help readers and clients understand the market on a global scale.

Morever, during the forecast period, the report also mentions the expected CAGR of the global market. The report provides readers with accurate historical statistics and forecast of the future.

The market has witnessed rapid development in the past and present years and is likely to expand in the near future. In the market report, there is a segment for the competitive landscape of the key players operating in the global industry. Overall, the report provides an in-depth insight into the 2020-2029 global Stem Cell Cartilage Regeneration market encompassing all important parameters.

Stem Cell Cartilage Regeneration Market research report offers a close watch on leading competitors with strategic analysis.

Global Market involves Top Key players such as: EMD Serono Inc, Merck KGaA, Xintela AB (publ), Theracell (Laboratories), BioTissue Technologies GmbH, Osiris Therapeutics Inc, Smith & Nephew plc, Orthocell Limited, Vericel Corporation and CellGenix GmbH

For Better Understanding, Download Free Sample Copy Of Stem Cell Cartilage Regeneration Market Report At:https://marketresearch.biz/report/stem-cell-cartilage-regeneration-market/request-sample

[***Are You A Start-Up, On The Way To Make It Vast? Grab an Exclusive Sample Copy Here***]

Furthermore, the Stem Cell Cartilage Regeneration market research report offers a complete analysis of the market segmentation on the basis of stem cell type, treatment, end user, and region.

Segmentation by stem cell type:

Hematopoietic Stem Cells (HSCs)Pluripotent Stem Cells (iPSC/ESCs)Mesenchymal Stem Cells (MSCs)Segmentation by treatment:

MicrofractureOsteochondral TransplantAutologous Chondrocyte ImplantationStem Cell InjectionsSegmentation by end user:

Hospitals & ClinicsAmbulatory Surgical Centers

Geographical Analysis:

The analyst of the report analyzed the market potential for each geographical region with respect to the consumer buying patterns, growth rate, demand, and present scenarios, macroeconomic parameters in the industry. Geographically, this report is subdivided into several regions, covering:

Europe: UK, Germany, France, Italy, Spain, and Russia.

North America: Canada, United States, and Mexico.

South & Central America: Argentina, Chile, and Brazil.

Middle East & Africa: Egypt, Saudi Arabia, UAE, Turkey, and South Africa.

Asia-Pacific: China, Japan, India, South Korea, Indonesia, Singapore, and Australia.

Owning our reports will help you to solve the following issues:

1. Uncertainty and doubt about the future market?

Our research report help our clients to foresee upcoming revenue pockets and growth areas. This helps our clients to invest or divest their resources.

2. Understanding market principles?

It is essential to have a fair understanding of market principles for a strategy. Our insights spot a light on market sentiment. We keep this observation by engaging with opinion leaders of a value chain of each industry we track.

3. Awareness of the most reliable investment centers?

Our research ranks investment centers of the market by considering their future demands, returns, and profit margins. By procuring our market research report our clients can focus on the most prominent investment centers.

4. assessment of potential business partners?

This research report help organization in identifying compatible business partners.

Why Should Buy This Report?

Get a comprehensive understanding of the Stem Cell Cartilage Regeneration market, the dynamics of the market and current state of the sector

To Strategize marketing, market-entry, market expansion and other business plans by understanding the factors driving the growth of the market

Be informed regarding the key developments in the Stem Cell Cartilage Regeneration market and the prime opportunity areas

Understand top competitors business and market dynamics, and respond accordingly

Customize Report AndInquiry For The Stem Cell Cartilage Regeneration Market Report:https://marketresearch.biz/report/stem-cell-cartilage-regeneration-market/#inquiry

If you have any special requirement regarding this report please let us know we will offer you a report as per your requirement.

At the end, the Stem Cell Cartilage Regeneration market report is an authentic source for gaining the market research that is likely to exponentially accelerate your business. The report gives the principle locale, economic situations coupled with benefit, limit, item value, generation, supply, request, and market development rate, figure and so on. The Stem Cell Cartilage Regeneration report additionally presents a new task SWOT examination, speculation attainability investigation, and venture return investigation.

About Us:

MarketResearch.biz is one spot destination for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We provide customized reports as per the requirements of our clients. Our inventory of research reports caters to various industry verticals including Technology and Media, Healthcare, Information, and Communication Technology (ICT), Chemicals, Materials, Energy, Heavy Industry, etc.

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry@marketresearch.biz

See the original post here:
Who are the Stem Cell Cartilage Regeneration Market Global Key Players? What are the Challenges and Threats Faced by Players? - Sound On Sound Fest

In all sorts of animals, from fruit flies to mice to elephants, cells follow fairly similar sets of steps to grow from embryo to adult. But while these steps follow the same order and often involve the same kinds of genes and molecular signals, they proceed at different rates from species to species.

A mouse gestates in about 20 days; a human takes about nine months. An African elephant remains in the womb for nearly two years. And in step with their sizes speaking broadly goes the speed at which cells in their bodies develop.

So what are the timers that keep things trucking along at the right rate for any given organism, ensuring that it grows to the proper size and with all its parts in place? Its a question that James Briscoe, a developmental biologist at the Francis Crick Institute in London, would love to answer.

Take one lone example among many: motor neurons, the nerves that make muscles contract. These develop from precursor cells over a few days in mice but a week or two in humans and the same thing happens when the cells are grown in a dish. We can look at this carefully and demonstrate its the same genetic process, the same gene activities, the same mechanisms involved, and its just running slower in humans than in mouse embryos, Briscoe says. Were trying to tackle that problem.

In a 2018 review published in the journal Development, Briscoe and developmental biologist Miki Ebisuya, now at EMBL Barcelona, explored where the fields understanding of developmental time currently stands. Its a two-part question, Briscoe explains.

First of all, for bodies to properly form, events must unfold in the right sequence: A before B, and B before C, and so on, at right times all over the developing body. Though theres much still to know, scientists have amassed plenty of knowledge on this problem, especially (but not exclusively) in closely studied creatures like the roundworm Caenorhabditis elegans and the fruit fly Drosophila melanogaster.

For example, theres a crisp order in how Drosophila neurons develop from stem cells in a part of the embryo called the ventral nerve cord. The stem cells produce neurons with different identities, one after the other; all of them develop, from the same pool of stem cells, just at different times, and once its time for the later types, theres no going back to making earlier ones. Theyre guided through this process by the sequential rise and fall of activity of a set of key genes.

The second aspect of timing is far more mysterious: the molecular processes setting the tempo such that clocks run faster or slower in different species.

Scientists already have identified types of clocks in sundry tissues. Speaking generally, such molecular timers either count up by steadily increasing the levels of a critical regulator until it exceeds a threshold, or count down by gradually decreasing the levels of an inhibitor, Ebisuya and Briscoe write.

Rats, for instance, use a count up timer to kick off brain-cell development in the embryo. As cells divide, chemicals that inhibit cell division gradually build up in the precursors to types of brain cells called oligodendrocytes. Once the inhibitors reach a key threshold level, the rat brain stops making new precursor cells and existing cells start to take on their mature forms.

In contrast, the African clawed frog Xenopus laevis employs a count down timer at a stage when that frog-to-be is a tiny ball of cells. Substances that spur cell division are diluted by speedy divisions until theyre so scarce that division slows and the next phase of embryo development kicks off.

Some clocks run through feedback loops, wherein proteins build up to a certain level and then act to shut down their production creating cyclical oscillations that cells can harness to drive developmental steps. Vertebrates of all kinds depend on an oscillating clock of this type to create the right number of structures called somites, which later develop into the bones and muscles of the vertebral column. (For more on this segmentation clock, one of the best-studied examples of developmental timing, see this related article in our special report.)

And in other cases, cells seem to keep track of how many times theyve divided, says developmental biologist Mubarak Hussain Syed of the University of New Mexico, who studies the timing of gene activity during Drosophila early brain development. The cell might be counting, OK, we have done 20 divisions, and now its time for the next step, he says.

Despite their strikingly different neck lengths, the giraffe and its nearest relative, the okapi, both have the same number of neck bones, called cervical vertebrae. The vertebrae are merely longer in the giraffe. Scientists believe that changes in the timing of developmental events (slowing down growth of one part relative to another, for example) had a huge part to play in the evolution of species.

CREDIT: ASIANINVASION12 / WIKIMEDIA COMMONS

Whatever the mechanisms, external signals not just clocks inside lone cells are involved to keep everything in step. Drosophila larvae, for example, contain multiple clumps, or discs, of tissue that develop into structures of the adult fly: a pair of discs for the wings, another pair for the eyes, and so on. If one of the wing discs is damaged, scientists observe that development is delayed to give the disc time to repair.

Todays modern technologies, including the ability to culture not just cells but mini-organs in dishes, should yield many clues. One might, for example, be able to add neuronal stem cells from one creature to a mini-brain of another and see if the foreign tissue develops at its own rate or changes its pace to match the cells that surround it, Syed says.

And the findings keep coming. Briscoes team recently posted unpublished results in the online archive BioRxiv suggesting that the difference in the pace of embryonic development of mice and humans may be caused by differences in protein stability between the two species. The differences appear to prolong the duration of the cell cycle in human cells.

Zooming in on details could yield a vast view. Scientists believe that changes in developmental timing heterochronies, as they are called had profound roles to play in the evolution of the diversity in body shapes and proportions we see in modern creatures. Snakes, for example, have many more vertebrae than do mice; they achieve this by running their segmentation clock at a faster clip relative to the development of other body parts. Giraffes come by their long necks another way: They have the same number of cervical vertebrae as their closest relatives, okapi, but those vertebrae are given more time to grow large.

By revealing the molecular clocks that time growth, biologists may start to understand the influences that gave the world mice, humans and elephants to begin with.

Here is the original post:
How does the embryo make all its parts at just the right moments? - Knowable Magazine

Harshini Mukundan, PhD, juggles a dizzying number of responsibilities while somehow making it all look effortless.

As an administrator in the Chemistry Division at Los Alamos National Laboratory, she serves as Deputy Group Leader for Physical Chemistry and Applied Spectroscopy and Team Leader in Chemistry for Biomedical Applications. The 2003 graduate from UNM's Biomedical Sciences Graduate Program is also a teacher, as well as a devoted parent and spouse, who, in her spare time, participates in traditional Indian dance.

But in her role as a research scientist, Mukundan is laser-focused on finding solutions to some of the most urgent health concerns facing humanity. At LANL she has developed diagnostic assays for tuberculosis and helped create technology to detect breast cancer and influenza. Her current highly ambitious research agenda centers on finding a universal method for identifying infectious disease.

Munkundans lab has unraveled some of the common methods by which disease-causing organisms interact with a human host in hopes of creating a mechanism to mimic what the body already does naturally.

All pathogens support or secrete biomarkers that are recognized by our innate immune system, she says, adding that many of these molecules are highly conserved. The body recognizes conserved signatures. It looks at the commonality and uses that to mount a response.

These molecules are not easily detected in the bloodstream, but they are carried throughout the body by hitchhiking on HDL and LDL cholesterol proteins (My buzzword for them is the biological taxi service, she says).

Mukundan and her collaborators are working on sensor technology that can liberate these biomarkers from their cholesterol hosts and measure them, providing a rapid readout of what type of infection theyre signaling.

While the labs work has national defense applications, it also has obvious relevance in clinical health care and is already being assessed for its use in diagnosing disease in the field. It has been tested in South Korea, Uganda and Kenya, Mukundan says, and could provide a quick way to distinguish a bacterial from a viral infection.

Mukundans path to a leadership role at the nations premier national laboratory started in a small town in the Indian state of Tamil Nadu, where her father was in banking and her mother was a teacher.

She earned her undergraduate degree in microbiology from the University of Delhi in 1995. It seemed cool, she says. I liked biology and I always wanted to do medicine or biology. She went on to complete a masters in microbiology at Barkatullah University in Bhopal, with her thesis research conducted at Indias National Institute of Immunology.

Her lab work there centered on drug-resistant cancer cell lines. There were pretty awesome researchers working at NII, Mukundan says. I got to meet a lot of really cool people. Essentially, it was just the exposure, and then I decided I wanted to do a PhD.

She and her husband, LANL staff scientist Rangachary Mukundan, came to the U.S. for their doctoral work. He earned his PhD in materials science at the University of Pennsylvania and joined LANL as a postdoctoral fellow in 1997.

Harshini initially was accepted at Penn for her PhD, but transferred to The University of New Mexico when her husband got his job at Los Alamos. As a late arrival in UNMs Biomedical Sciences Graduate Program, she started by rotating through several labs, where she met Nancy Kanagy, PhD, now chair of the Department of Cell Biology & Physiology.

I really liked Nancy, Mukundan says. I liked her work ethic and approach to balance. She has this way of making you feel very welcome.

At the time, Kanagy was working on alpha adrenergic receptors and their role in cardiovascular disease, which Mukundan found interesting. Mukundan started by exploring a hypothesis involving the movement of calcium ions in cells that soon turned out to be incorrect.

I definitely proved that the hypothesis was wrong, she says. We got a paper out of it, but that research was at a dead end. We had to make a project change.

With Kanagy and fellow Cell Biology professor Thomas Resta, Mukundan devised a new project. It was looking at gender differences in hypertension and the role of estrogen in erythropoietin regulation, she says.

In putting together the research proposal that would lead to her dissertation on how estrogen regulates of erythropoietin gene expression during hypoxia. Nan and Tom were heavily involved and helped a lot, obviously, and we got it, she says, adding that the setback taught her a valuable lesson.

It looks like a big bummer when your original project doesnt work, but in retrospect, I learned how to write, she says. It made me altogether much more confident. Sometimes you have what appears to be a big tragedy but it actually works out for the better.

Mukundan says she experienced some reactions when she first came to the U.S. that were a little bit racist, she sometimes felt she was treated differently because she was a woman. But at UNM she felt supported.

In Nan and Toms team I found acceptance, Mukundan says. Kanagy, who was starting a family, became a friend and mentor. I think it kind of subconsciously does teach you that women can be great scientists, good mothers and perpetually tired.

Mukundan and her husband lived in Santa Fe while she was doing her lab research, requiring a daily commute to the UNM campus in Albuquerque. She stayed at my house, Kanagy recalls. Sometimes it was really late to drive back to Santa Fe.

Mukundan showed an aptitude for research, Kanagy says. Harshini was unafraid of challenges, she recalls. Early on, she was not daunted by having a hard problem to solve and taking this on. She used very creative approaches.

Mukundan was unflappable in the face of the failure of her first research project, Kanagy says. Courageous might be the right word or at least unintimidated by difficulty, she says. When we she had to switch gears she was very resilient. She developed a whole bunch of new methods to answer this question.

Kanagy also appreciates her friends ability to keep the many commitments in her life in balance.

Shes very human and cared very deeply about her family and cared about my family, she says. Even then, she was doing traditional Indian dance while commuting an hour each way. When I think of Harshini, she has a great smile and she just invites people in shes just a pleasure to have around.

When Mukundan defended her dissertation in 2002, soon after having her first child, Kanagy urged her to pursue postdoctoral research at another university, but Mukundan instead took a job at QTL Biosystems, Santa Fe a biotech startup, where she worked for two years on biosensor technology.

In 2006 Mukundan won a postdoctoral position at LANL in the lab of Dr. Basil Swanson, where she wrote a National Institutes of Health grant for research on developing a diagnostic tool for tuberculosis. We got that proposal and I still work on TB today, she says. Thats how we got started.

After graduating to become a full member of the LANL faculty, Mukundan has become a mentor in her own right. Earlier this year, she was recognized as one of 125 IF/THEN Ambassadors by the American Association for the Advancement of Science for her support of young women in science, technology, engineering and math (STEM) at LANL.

IF/THEN is a national initiative of Lyda Hill Philanthropies that seeks to further women in STEM fields by recognizing innovators and inspiring the next generation of researchers.

Although scientific careers can be incredibly demanding, Mukundan says she learned from her UNM colleagues you can have a good career and have a family and have work-life balance. That makes people want to go into science.

More here:
Life in the Balance - HSC Newsbeat